Tuberc Respir Dis.  2004 Aug;57(2):125-131. 10.4046/trd.2004.57.2.125.

Construction of Recombinant BCGs Overexpressing Antigen 85 Complex and Their Protective Efficacy against Mycobacterium tuberculosis Infection in a Mouse Model

Affiliations
  • 1Department of Molecular Biology, Korean Institute of Tuberculosis, Seoul, Korea. gbai@hotmail.com
  • 2Department of Microbiology, Yonsei University College of Medicine, Seoul, Korea.
  • 3Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, Wonju, Korea.
  • 4Department of Biochemistry and Molecular Biology, College of Science Technology, Hanyang University, Ansan, Korea.

Abstract

Tuberculosis (TB) remains an enormous global health problem, and a new vaccine against TB more potent than the current inadequate BCG vaccine is urgently needed. We constructed three recombinant Mycobacterium bovis BCG (rBCG) strains over-expressing antigen (Ag) 85A, Ag85B, or both of M. tuberculosis using their own promoter and secretory sequence, or hsp60 promoter. SDS-PAGE analysis of rBCG proteins showed over-expression of Ag85A and Ag85B proteins in higher level than of those in their parental strain of BCG. In addition, rBCG(rBCG/B.FA) over-expressing Ag85A and Ag85B induced strong IFN-gamma production in splenocytes. However, there was no significant difference in protective efficacy between rBCG and their parental BCG strain. In this study, therefore, rBCG over-expressing Ag85A, Ag85B, or both failed to show enhanced protection against M. tuberculosis infection in a mouse model.

Keyword

Tuberculosis; Vaccine; Recombinant BCG

MeSH Terms

Animals
BCG Vaccine
Electrophoresis, Polyacrylamide Gel
Humans
Mice*
Mycobacterium bovis*
Mycobacterium tuberculosis*
Mycobacterium*
Parents
Tuberculosis
BCG Vaccine
Full Text Links
  • TRD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr